Interest of genotyping and phenotyping of drug-metabolizing enzymes for the interpretation of biological monitoring of exposure to styrene

Pharmacogenetics

Volumn 12, Issue 9, 2002, Pages 691-702

  Haufroid, Vincent ^a   Jakubowski, Marek ^b   Janasik, Beata ^b   Ligocka, Danuta ^a,b   Buchet, Jean Pierre ^a   Bergamaschi, Enrico ^c   Manini, Paola ^c   Mutti, Antonio ^c   Ghittori, Sergio ^d   Arand, Michael ^e   Hangen, Nina ^e   Oesch, Franz ^e   Hirvonen, Ari ^f   Lison, Dominique ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^c UNIVERSITY OF PARMA   (Italy)

^d IRCCS   (Italy)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

Author keywords

Biological monitoring; Cytochrome P4502E1; Epoxide hydrolase; Genetic polymorphisms; Glutathione transferase; Mercapturic acids; Styrene

Indexed keywords

ACETYLCYSTEINE DERIVATIVE; BIOLOGICAL MARKER; CYTOCHROME P450 2E1; DRUG METABOLIZING ENZYME; EPOXIDE HYDROLASE 1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; MESSENGER RNA; PHENYLHYDROXYETHYLMERCAPTURIC ACID; STYRENE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BIOLOGICAL MONITORING; BIOTRANSFORMATION; BLOOD ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; GENE FREQUENCY; GENOTYPE; HUMAN; MALE; NORMAL HUMAN; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; URINARY EXCRETION;

ACETYLCYSTEINE; ADULT; BIOLOGICAL MARKERS; CYTOCHROME P-450 CYP2E1; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; EPOXIDE HYDROLASES; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; GLYOXYLATES; HUMANS; ISOENZYMES; LYMPHOCYTES; MALE; MANDELIC ACIDS; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; STYRENE;

EID: 12244306891     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200212000-00003     Document Type: Article

References (51)

1. Limasset JC, Simon P, Poirot P, Subra I, Grzebyk M. Estimation of the percutaneous absorption of styrene in an industrial situation. Int Arch Occup Environ Health 1999; 72:46-51.
2. Threshold limit values (TLVs) for chemical substances and physical agents and biological exposure indices (BEIs) for 2000. Cincinnati, OH: ACGIH, American Conference of Governmental Industrial Hygienists; 2000.
3. Some industrial chemicals, Volume 60. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, France: International Agency for Research on Cancer; 1994. pp. 233-320.
4. Jenkins Sumner S, Fennell TR. Review of the metabolic fate of styrene. Crit Rev Toxicol 1994; 24:S11-33.
5. Ghittori S, Maestri L, Imbriani M, Capodaglio E, Cavalleri A. Urinary excretion of specific mercapturic acids in workers exposed to styrene. Am J Indust Medicine 1997; 31:636-644.
6. Wieczorek H, Piotrowski JK. Evaluation of low exposure to styrene.I. Absorption of styrene vapours by inhalation under experimental conditions. Int Arch Occup Environ Health 1985; 57:57-69.
7. Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991; 4:168-179.
8. Nakajima T, Elovaara E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, et al. Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450. Chem Res Toxicol 1994; 7:891-896.
9. Kim H, Wang RS, Elovaara E, Raunio H, Pelkonen O, Aoyama T, et al. Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica 1997; 27:657-665.
10. Nakajima T, Elovaara E, Gonzalez FJ, Gelboin HV, Vainio H, Aoyama T. Characterization of the human cytochrome P450 isozymes responsible for styrene metabolism. IARC Sci Publ 1993; 127:101-108.
11. Wenker mandelic acid, Kezic S, Monster AC, De Wolff FA. Metabolism of styrene in the human liver in vitro: Interindividual variation and enantio-selectivity. Xenobiotica 2001; 31:61-72.
12. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 1990; 3:566-573.
13. Rannug A, Alexandrie AK, Persson I, Ingelman Sundberg M. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: Regulation and toxicological significance. JOEM 1995; 37:25-36.
14. Kim RB, O'Shea D, Wilkinson GR. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 1995; 57:645-655.
15. Lucas D, Menez C, Girre C, Berthou F, Bodenez P, Joannet I, et al. Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics 1995; 5:298-304.
16. Haufroid V, Gardinal S, Licot C, Villalpando ML, Van Obbergh L, Clippe A, et al. Biological monitoring of exposure to sevoflurane in operating room personnel by the measurement of hexafluoroisopropanol and fluoride in urine. Biomarkers 2000; 5:141-151.
17. Lieber CS Cytochrome P-4502E1: Its physiological and pathological role. Physiol Rev 1997; 77:517-544.
18. Streetman DS, Bertino Jr JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: A review of in vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10:187-216.
19. Palmer JL, Scott RJ, Gibson A, Dickins M, Pleasance S. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). Br J Clin Pharmacol 2001; 52:555-561.
20. Raucy JL, Schultz ED, Kearins MC, Arora S, Johnston DE, Omdahl JL, et al. CYP2E1 expression in human lymphocytes from various ethnic populations. Alcohol Clin Exp Res 1999; 23:1868-1874.
21. Yano H, Tsutsumi M, Fukura M, Chen WB, Shimanaka K, Tsuchishima M, et al. Study of cytochrome P4502E1 mRNA level of mononuclear cells in patients with alcoholic liver disease. Alcohol Clin Exp Res 2001; 25:2S-6S.
22. Haufroid V, Toubeau F, Clippe A, Buysschaert M, Gala JL, Lison D. Real-time quantification of cytochrome P4502E1 mRNA in human peripheral blood lymphocytes by reverse transcription-PCR: Method and practical application. Clin Chem 2001; 47:1126-1129.
23. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: Genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 1994; 3:421-428.
24. Wenker MA, Kezic S, Monster AC, De Wolff FA. Metabolism of styrene-7,8-oxide in human liver in vitro: Interindividual variation and stereochemistry. Toxicol Appl Pharmacol 2000; 169:52-58.
25. Omiecinski CJ, Aicher L, Holubkov R, Checkoway H. Human peripheral lymphocytes as indicators of microsomal epoxide hydrolase activity in liver and lung. Pharmacogenetics 1993; 3:150-158.
26. Hassett C, Lin J, Carty CL, Laurenzana EM, Omiecinski CJ. Human hepatic microsomal epoxide hydrolase: Comparative analysis of polymorphic expression. Arch Biochem Biophys 1997; 337:275-283.
27. Haufroid V, Buchet JP, Gardinal S, Ghittori S, Imbriani M, Hirvonen A, et al. Importance of genetic polymorphisms of drug-metabolizing enzymes for the interpretation of biomarkers of exposure to styrene. Biomarkers 2001; 6:236-249.
28. De Palma G, Manini P, Mozzoni P, Andreoli R, Bergamaschi E, Cavazzini S, et al. Polymorphism of xenobiotic-metabolizing enzymes and excretion of styrene-specific mercapturic acids. Chem Res Toxicol 2001; 14:1393-1400.
29. Sundberg K, Johansson AS, Stenberg G, Widersten M, Seidel A, Mannervik B, et al. Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis 1998; 19:433-436.
30. Zimniak P, Nanduri B, Pikula S, BandorowiczPikula J, Singhal SS, Srivastava SK, et al. Naturally-occurring human glutathione-S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymatic properties. Eur J Biochem 1994; 244:893-899.
31. AliOsman F, Akande O, Antoun G, Mao JX, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants - Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 1997; 272:10004-10012.
32. Uematsu F, Kikuchi H, Ohmachi T, Sagami I, Motomiya M, Kamataki T, et al. Two common RFLPs of the human CYP2E gene. Nucl Acids Res 1991; 19:2803.
33. McBride OW, Umeno M, Gelboin HV, Gonzalez FJ. A Taql polymorphism in the human P450IIE1 gene on chromosome 10 (CYP2E). Nucl Acids Res 1987; 15:10071.
34. Haufroid V, Clippe A, Knoops B, Bernard A, Lison D. Genotyping in urine: An interesting tool for epidemiological studies. Clin Chem 1998; 44:2210-2211.
35. Arand M, Muhlbauer R, Hengster J, Jager E, Fuchs J, Winkler L, et al. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem 1996; 236:184-186.
36. Saarikoski ST, Voho A, Reinikainen M, Anttila S, Karjalainen A, Malaveille C, et al. Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. Int J Cancer 1998; 77:516-521.
37. Lancaster JM, Brownlee HA, Bell DA, Futreal PA, Marks JR, Berchuck A, et al. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog 1996; 17:160-162.
38. Yoshikawa M, Hiyama K, Ishioka S, Maeda H, Maeda A, Yamakido M. Microsomal epoxide hydrolase genotypes and chronic obstructive pulmonary disease in Japanese. Int J Mol Med 2000; 5:49-53.
39. Spurdle AB, Purdie DM, Webb PM, Chen XQ, Green A, Chenevix-Trench G. The microsomal epoxide hydrolase Tyr113His polymorphism: Association with risk of ovarian cancer. Mol Carcinog 2001; 30:71-78.
40. Manini P, Andreoli R, Bergamaschi E, De Palma G, Mutti A, Niessen WMA. A new method for the analysis of styrene mercapturic acids by liquid chromatography/electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom 2000; 14:2055-2060.
41. Vodicka P, Soucek P, Tates AD, Dusinska M, Sarmanova J, Zamecnikova M, et al. Association between genetic polymorphisms and biomarkers in styrene-exposed workers. Mutation Research 2001; 482:89-103.
42. Persson I, Johansson I, Bergling H, Dahl ML, Seidegard J, Rylander R, et al. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett 1993; 319:207-211.
43. Sarmanova J, Tynkova L, Susova S, Gut I, Soucek P. Genetic polymorphisms of biotransformation enzymes: Allele frequencies in the population of the Czech Republic. Pharmacogenetics 2000; 10:781-788.
44. Lan Q, Chow WH, Lissowska J, Hein DW, Buetow K, Engel LS, et al. Glutathione S-transferase genotypes and stomach cancer in a population-based case-control study in Warsaw, Poland. Pharmacogenetics 2001; 11:655-661.
45. Baxter SW, Choong DYH, Campbell IG. Microsomal epoxide hydrolase polymorphism and susceptibility to ovarian cancer. Cancer Letters 2002; 177:75-81.
46. Haufroid V, Buchet JP, Gardinal S, Lison D. Cytochrome P4502E1 phenotyping by the measurement of the chlorzoxazone metabolic ratio: Assessment of its usefulness in workers exposed to styrene. Int Arch Occup Environ Health 2002; 75:453-458.
47. Ollikainen T, Hirvonen A, Norppa H. Influence of GSTT1 genotype on sister chromatid exchange induction by styrene-7,8-oxide in cultured human lymphocytes. Environ Mol Mutagen 1998; 31:311-315.
48. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994; 300:271-276.
49. Lucas D, Ferrara R, Gonzalez E, Bodenez P, Albores A, Manno M, et al. Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. Pharmacogenetics 1999; 9:377-388.
50. Wenker MA, Kezic S, Monster AC, De Wolff FA. Metabolic capacity and interindividual variation in toxicokinetics of styrene in volunteers. Hum Exp Toxicol 2001; 20:221-228.
51. Carlson GP, Perez Rivera AA, Mantick NA. Metabolism of the styrene metabolite 4-vinylphenol by rat and mouse liver and lung. J Toxicol Environ Health A 2001; 63:541-551.